Live Breaking News & Updates on Clinical Research Team
Stay updated with breaking news from Clinical research team. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
On saturday alone. Now measures are being taken to slow the spread, with miami beach enacting a new curfew overnight. We will have the latest in a live report from south florida just ahead. Then in our sunday focus, a conversation about the life of john lewis, with historian john meacham who speak with the congressman in recent weeks while finishing a new book on the civil rights icon. Plus, in our sundays spotlight, with some promising news this week about a potential Coronavirus Vaccine, how soon could it be approved, and how long will it take to produce and distribute across the country . And later, a brand new virtual sunday sitdown with captain america himself, chris evans, on his hit series defending jacob. His new step into politics, and his oneman dance parties during this long lockdown. Im a big proponent of just you know, its sunny outside, i start jammin and looking like a lunatic really. A sunday sitdown with chri ....
Faron Pharmaceuticals Oy: Initial positive data from Phase 2 of BEXMAB arvopaperi.fi - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from arvopaperi.fi Daily Mail and Mail on Sunday newspapers.
Retrospective, real-world results showed that patients treated with oral decitabine and cedazuridine and standard parenteral hypomethylating agents (HMAs) for myelodysplastic syndrome (MDS) demonstrated similar levels of comorbidities and disease burden to patients treated with intravenous (IV)/subcutaneous (SC) HMAs. ....
Oral decitabine/cedazuridine and parenteral hypomethylating agents were associated with similar levels of comorbidities and disease burden in patients with myelodysplastic syndrome. ....
Drs Garcia-Manero and Zeidan discuss the significance of efficacy and safety data from the COMMANDS trial in myelodysplastic syndrome, takeaways from the subgroup analyses, and expectations around treatment sequencing in the lower-risk population. ....